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ABSTRACT: Shakuyakukanzoto (SKT), a traditional Japanese (Kampo) medicine, has been used by patients with muscle cramps and ab-
dominal pains. In this trial, we analyzed plasma concentrations of active components after SKT was administered as a single oral dose
of 2.5 or 5.0 g/day per person. The study was a randomized, open-label, two-arm, two-period, crossover trial conducted in healthy
Japanese volunteers. Albiflorin (ALB), paeoniflorin (PAE), glycycoumarin (GCM), isoliquiritigenin (ILG), glycyrrhetic acid (GA), and gly-
cyrrhetic acid-3-O-monoglucuronide were targeted, and the plasma concentration of each component was measured using a liquid
chromatography–tandem mass spectrometry method. The pharmacokinetic parameters were calculated, and the linearity was assessed.
All targeted components were detected in the plasma after oral administration of SKT. ALB, PAE, GCM, and ILG were detected at an
early stage. The linearity was observed for the maximum plasma concentration of GCM, ILG, and GA and for the area under the plasma
concentration–time curve of GA. In this trial, we demonstrated for the first time in humans that these components were absorbed into the
blood after oral administration of SKT. The results of this pharmacokinetic trial in humans are also important and useful for understanding
the mechanism of action of SKT, verifying the active components predicted in basic research, and conducting pharmacokinetics and safety
studies in the future. C© 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American
Pharmacists Association J Pharm Sci 104:3952–3959, 2015
Keywords: Clinical pahrmacokinetics; Dose-response; Intestinal absorption; Intestinal metabolism; Mebabolite kinetics;
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INTRODUCTION
Shakuyakukanzoto (SKT) is a “Kampo” traditional Japanese
medicine that has been approved by the Ministry of Labor,
Health, and Welfare. It comprises two types of crude drugs,
Glycyrrhizae radix and Paeoniae radix, and is widely used by
patients with muscle cramps and abdominal pains. In clini-
cal trials, SKT has been reported effective in alleviating mus-
cle pains, muscle cramps, joint pain, and numbness,1–3 and
its immediate potency in exerting these effects has also been
studied.4 Anticonvulsant effects in a rat spasticity model5
and antiallodynic and antinociception or analgesia effects in a
mouse allodyniamodel6,7 have been suggested as the pharmaco-
logical effects of SKT. Glycyrrhizae radix-derived glycyrrhetic
acid (GA), glycycoumarin (GCM), and isoliquiritigenin (ILG)
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are presumed to be active components, which are responsible
for anticonvulsive, analgesic, and muscle-relaxant effects,8–10
and Paeoniae radix-derived paeoniflorin (PAE) and albiflorin
(ALB) are presumed to be active components that are re-
sponsible for antinociceptive effects.6 In contrast, long-term
excessive ingestion of Glycyrrhizae radix is known to cause
pseudoaldosteronism or hypokalemia,11–14 and it has been sug-
gested that the causal components could beGA and glycyrrhetic
acid-3-O-monoglucuronide (3MGA), which is a metabolite of
glycyrrhizic acid (GL) present in Glycyrrhizae radix.15–18
To evaluate the pharmacological action and safety of SKT,
it is important to determine the pharmacokinetics of active
components after the administration. To date, Paeoniae radix-
derived components ALB and PAE and the Glycyrrhizae radix-
derived components GCM, ILG, GA, and 3MGA have been de-
tected in the blood of rats after single oral administration of
SKT.19–23 In humans, the same components have been detected
in the blood of human orally administered Paeoniae radix or
Glycyrrhizae radix.24–26 However, the pharmacokinetics of SKT
remains unclear. In Kampo medicine, there is a possibility
that the absorption and metabolism of components is regu-
lated by multiple constituent herbs and their interactions.27–30
Therefore, it is important to understand the pharmacokinetics
of the components while taking SKT as a mixture of herbal
medicines.
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Figure 1. Chemical structures of seven Shakuyakukanzoto-derived components and two internal standards.
In this randomized crossover trial, we investigated the phar-
macokinetics of herbal components in the blood after sin-
gle oral administration of SKT (2.5 or 5.0 g/day per person)
in 20 healthy adult trial volunteers. SKT-derived six target
components (ALB, PAE, GCM, ILG, GA, and 3MGA) were
selected with reference to the previously described pharma-
cokinetic trials in rats19 and Paeoniae radix or Glycyrrhizae
radix pharmacokinetic trials in humans,24–26 and the targeted
components were then measured using validated procedure for
the determination of the components.
MATERIALS AND METHODS
Chemicals and Reagents
Tsumura SKT extract granules for formulation (product code
TJ-68, lot H16612; Tsumura & Co., Tokyo, Japan) were used
for the investigation. The drug was manufactured according to
Good Manufacturing Practices and adapted to factory release
testing. This herbal preparation (7.5 g) contains 2.5 g of spray-
dried hot water extract of a mixture of two crude drugs: Paeo-
niae radix (6.0 g) and Glycyrrhizae radix (6.0 g). The standard
components present in SKT, that is, ALB, PAE, GL, and GA
were purchased fromWako Pure Chemical Industries, Ltd. (Os-
aka, Japan); ILGwas purchased from Tokyo Chemical Industry
Company, Ltd. (Tokyo, Japan); 3MGA was purchased from Na-
gara Science (Gifu, Japan); GCM was supplied by Tsumura
& Co. Atractylenolide III (Tsumura & Co.), digoxin (Sigma–
Aldrich, St. Louis, Missouri), niflumic acid (Sigma–Aldrich),
and 6′-O-acetyl PAE (Tsumura & Co.) were used as internal
standard (IS). Figure 1 shows the chemical structures of these
nine compounds. Other chemicals were purchased from com-
mercial sources.
Liquid Chromatographic Assay of Five Components Contained
in SKT
The SKT formulation (0.5 g) was suspended in 25 mL of
acetonitrile (MeCN)–purified water (1:1, v/v) and ultrasoni-
cated for 15 min. The suspension was centrifuged at 1700g
for 15 min, and the supernatant was collected. The residue was
re-extracted using 25 mL of methanol (MeOH)–purified water
(1:1, v/v). The first and second supernatants were combined, fil-
tered (0.22 :m), and diluted with extracted solution as the test
substance solution. An aliquot (5 :L) of test substance solution
was injected into a liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) system. The LC–MS/MS system com-
prised an LC-20A system (Shimadzu, Kyoto, Japan) connected
to an API5000 triple quadrupole mass spectrometer fitted with
a TurboIonSpray electrospray ionization interface (AB Sciex,
Framingham, Massachusetts). A SUMIPAX ODS Z-CLUE col-
umn (2 × 50 mm, 3 :m; Sumika Chemical Analysis Service,
Ltd., Tokyo, Japan) was used for all components at 40°C. The
mobile phases comprised solution A (10 mmol/L ammonium
acetate buffer) and solution B (MeOH), and the flow rate was
0.35 mL/min. The analytical methods are summarized in Sup-
plemental Table S1.
Clinical Trial Design
This clinical trial was a randomized, open-label, two-arm, two-
period design (Fig. 2). With regard to inclusion criteria, the
studies included healthy Japanese adults aged 20–45 years
with a body mass index between 18 and 25 who were willing
and able to comply with the study requirements. The exclusion
criteria for this study included a history of significant liver,
heart, or vessel disease and consumption of supplements that
contained any SKT component or any drug within 3 days to
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Figure 2. Flow diagram for the subjects in this randomized crossover
study.
1 week before the first dose. Other standard exclusion criteria
included relevant allergies and any alcohol or nicotine use. The
sample size was selected to allow characterization of the safety
and pharmacokinetics of SKT components in healthy Japanese
volunteers. Twenty subjects (age, 21–42 years; height, 163.9–
182.1 cm;weight, 53.8–76.3 kg; andBMI, 18.6–24.7 kg/m2)were
randomized into two groups (10 subjects/group). The safety end-
point was evaluated in all subjects. This endpoint was defined
on the basis of a physician’s judgment after examination or ob-
servation that a serious adverse event had occurred. Adverse
events included death, a life-threatening event, an event re-
quiring hospitalization for treatment or an extended stay in
hospital, an event resulting in permanent or temporary dis-
ability or dysfunction, an event resulting in a congenital ab-
normality, or any other serious medical phenomenon. With re-
spect to side effects, no specific conditions were defined, and
all adverse events for which no causal relationship with the
drug could be excluded were deemed to be side effects. In each
stage during the 48-h period following SKT administration,
the physician monitored the subject for subjective symptoms,
objective findings, swelling, body temperature (axillary), blood
pressure (sitting), and pulse (sitting). The physician also con-
ducted a hematological examination formeasuring the subject’s
red blood cell, leucocyte and platelet counts, hemoglobin level,
hematocrit value, and prothrombin time. A biochemical exami-
nation was performed for determining total protein, blood urea
nitrogen, creatinine, uric acid, aspartate aminotransferase, ala-
nine aminotransferase, total bilirubin, alkaline phosphatase,
(-glutamyltranspeptidase, albumin, total cholesterol, C-
reactive protein, potassium, sodium, chlorine, and creatine
phosphokinase to identify any abnormalities associated with
the subject’s condition prior to administration. All subjects
fasted for 12 h before administration and 4 h after adminis-
tration of the study drug. The subjects ate a controlled diet
without SKT components from 3 days before the start of the
study till the day of completion.
In this quantitative trial, 12-mL blood samples were col-
lected at 0 (preadministration), 5, 15, and 30 min, and 1, 2, 4,
8, 10, 12, 14, 24, and 48 h after a single oral dose of SKT formu-
lation (2.5 or 5.0 g). The trial subjects were hospitalized in this
study. The blood was immediately centrifuged at 1700g and 4°C
for 15 min to obtain plasma. The plasma fractions were stored
at −20°C or lower until LC–MS/MS analysis.
Ethics Statement
The studies were conducted at the Medical Corporation Shi-
nanokai ShinanozakaClinic in two periods: January andFebru-
ary, 2014, respectively. The studies were approved by the Medi-
cal Corporation Shinanokai Shinanozaka Clinic and conducted
in accordance with ethical norms prescribed in the Declaration
of Helsinki and Good Clinical Practice guidelines. Before ini-
tiation of the studies, informed consent was obtained from all
subjects.
LC–MS/MS Analysis of SKT-derived Components in the Plasma
The plasma concentrations of all components were determined
using LC–MS/MS. The instrument was composed of a LC-20AD
System with a QTRAPR©5500 system (AB Sciex) or Shimadzu
LC system (Degasser, DGU-14A; Column oven, CTO-10ASvp;
Pump, LC-10ADvp; Autosampler, SIL-HTc) and an API4000
system. An InertSustain C18 column (3 :m, 2.1 × 50 mm; GL
Sciences, Tokyo, Japan) was used for all components.
Sample Preparation
For quantification of ALB and PAE, 300 :L of the plasma sam-
ple were mixed with 15 :L of water and MeOH (1:1, v/v), 10 :L
of IS solution (100 ng/mL 6′-O-acethyl PAE), and 300 :L of puri-
fiedwater. Themixture was loaded onto anOasisHLB :Elution
Plate (30 :m; Waters Corporation, Milford, Massachusetts),
washed with 300 :L of purified water twice, and eluted with
100 :L of MeOH. Purified water (200 :L) was added to the
eluent. An aliquot (5 :L) of each sample was injected onto the
analytical column.
For quantification of GCM and ILG, 300 :L of the plasma
sample were mixed with 15 :L of 50% MeOH, 10 :L of IS so-
lution (100 ng/mL niflumic acid), and 1.2 mL of purified water.
The mixture was loaded onto a solid-phase column (Oasis HLB
3 cc, 60 mg; Waters Corporation), washed with 3 mL of purified
water, and eluted with 2 mL of acetic acid–MeOH (5:1000, v/v).
The eluate was dried at 40°C in a water bath under a stream of
nitrogen gas. A 10-mmol/L ammonium acetate–MeOH (6:4, v/v;
150 :L) was added to the dried sample and mixed. The recon-
stitution sample was filtered (0.2 :m), and an aliquot (20 :L)
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of the mixture was injected onto the analytical column. For
quantification of GA and 3MGA, 200 :L of the plasma sam-
ples were mixed with 10 :L of 50% MeCN, 10 :L of IS solution
(100 ng/mL niflumic acid), 500 :L of formic acid–purified water
(1:100, v/v), and 3 mL of tert-butyl methyl ether. The mixture
was centrifuged at 1800g and 4°C for 2 min. The aqueous layer
was frozen in a dry-ice/MeOH bath. The supernatant was col-
lected in a test tube and dried at 40°C in a water bath under
a stream of nitrogen gas. A 10-mmol/L ammonium acetate–
MeCN (1:2, v/v; 200 :L) was added to the dried sample and
mixed. An aliquot (2 :L) of the mixture was injected onto the
analytical column.
Analysis Conditions
The analytical methods are summarized in Supplemental
Table S2.
Validation for Quantitative Determination of SKT-derived
Components in the Plasma
To assure the quality of the quantitative data by LC–MS/MS of
the components in the plasma, the analytical methods, includ-
ing the specificity, recovery, intraday and interday reproducibil-
ity, calibration curve, stability in blood, short- and long-term
stability, postpreparative stability, freeze–thaw stability, dilu-
tion integrity, matrix effect, carryover, limit of quantification,
and stability in the standard solution, were validated according
to the US Food and Drug Administration Guidance for Indus-
try Bioanalytical Method Validation.31 The validation data are
summarized in Supplemental Table S3.
Pharmacokinetics Analysis
Measured values of each component in the plasma were an-
alyzed by noncompartmental modeling using Phoenix Win-
Nonlin (version 6.3; Certara L.P., St. Louis, Missouri) for de-
termining various pharmacokinetic constants, including the
maximum plasma concentration (Cmax), time to maximum
plasma concentration after drug administration (tmax), appar-
ent elimination half-life (t1/2), and the area under the plasma
concentration–time curve from zero to the last observation time
(AUC0–last). The t1/2 was divided by loge2/ke, where ke is the ter-
minal elimination (at least three data points on the descending
linear limb) rate constant. Component plasma concentration
was treated as zero when the peak was below the limit of quan-
titation. The plasma concentration, Cmax, AUC0–last, and t1/2 of
the target components in each group were presented as the
geometric mean [95% confidence interval (CI)]. The tmax data
were presented as the medians with range from minimum to
maximum.
Evaluation of Proportionality of SKT Dose and Pharmacokinetic
Parameters of Targeted Component
The dose proportionality (linearity) of the orally administered
SKT dose and AUC0–last or Cmax of each component detected in
the blood was analyzed using the model shown in the following
formula (Eq. (1)).32,33 The model was fitted as a mixed-effects
model that included a random subject effect.
ln (PKij ) = : + aj + $ ln (dosei) + gij (1)
where PKij is the AUC0–last or Cmax at dose i (i = 1, 2) in the
subjects j (j = 1, 2, ..., n), : is the overall mean, aj is a random
subject effect that describes the individual difference for subject
j and assumed to be normally distributed around mean 0 with
variance Fa2, dosei is the administered dose (g) of the test drug,
and gij represents random error with mean 0 and variance F2.
$ is a parameter to be used for dose proportionality evaluation.
Inferences were made on the basis of the theoretical $ of 1.
Evaluation of linearity was performed using Phoenix WinNon-
lin and SAS 9.2 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Concentration of the Six Components Presented
in SKT Formulation
The concentrations of PAE, ALB, GCM, ILG, GL, and GA were
9920, 4370, 118, 79.3, 10,400, and 5.29 :g in 1 g of the SKT
formulation, respectively.
Registered Subjects
Twenty subjects were screened and enrolled. No adverse effect
was observed in any subject treated with SKT. No irregulari-
ties were found in the measured blood or biochemical examina-
tion items before or after SKT administration (Supplemental
Table S4).
Pharmacokinetics Analysis
Plasma Concentrations of the Six SKT-Derived Components
Glycycoumarin concentrations of one subject were BQL in the
plasma samples collected; therefore, this subject was excluded
from the analysis for GCM. Concentration of each component
and metabolite were BQL in the plasma of all subjects be-
fore SKT administration. The time profiles of plasma concen-
trations and pharmacokinetic parameters of six SKT-derived
components after oral administration of SKT formulation (2.5
and 5.0 g per person) to subjects are shown in Figure 3 and
Table 1, respectively. The highest plasma concentration was
found in GA followed by PAE, ALB, 3MGA, ILG, and GCM.
Rapid tmax values within 3 h after the administration of SKT
were found for ILG, GCM, ALB, and PAE. Thereafter, the con-
centrations of ALB and PAE decreased, and their t1/2 values
were 1.76–1.81 and 1.73–1.74 h, respectively. However, the t1/2
of ILG and GCM were considerably slower than those of ALB
and PAE because the concentrations of both components rein-
creased at approximately 8 h. In contrast, late tmax values were
found in 3MGA and GA, which are GL metabolites, and their
t1/2 values were 5.07–5.26 and 8.43–10.3 h, respectively.
Dose Proportionality Between SKT Doses and the
Pharmacokinetic Parameters of Target Components in the Plasma
In clinical pharmacological studies, the test drug is consid-
ered to show linear pharmacokinetics when AUC0–last and Cmax
proportionally increase with increasing dose. In the present
study, a power model fitted mixed-effect model was used for
assessing the dose proportionality between SKT doses and
plasma concentration (Cmax or AUC0–last) of the six components.
Table 2 shows the $ point estimates and 90% CI analyzed using
the mixed-effects model. In this study, linearity was recognized
when the 90% CI of $ included 1.
When the proportionality was examined between SKT dose
andCmax, the 90%CIs of $ values of GCM, ILG, andGA included
1, whereas those of ALB, PAE, and 3MGA were less than 0.5.
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Figure 3. Plasma concentrations of six Shakuyakukanzoto-derived components: (a) albiflorin, (b) paeoniflorin, (c) glycycoumarin, (d) isoliquir-
itigenin, (e) glycyrrhetic acid, and (f) glycyrrhetic acid 3-O-monoglucuronide. Blood samples were collected at 0 (before the administration), 5, 15,
and 30 min, and 1, 2, 4, 8, 10, 12, 14, 24, and 48 h after the administration of Shakuyakukanzoto (2.5 or 5.0 g/person). Each value represents an
arithmetic mean (n = 19–20).
When the linearity was examined between the SKT dose and
AUC0–last, the 90% CIs of $ values of GA included 1. However,
the 90% CIs of $ values of ALB, PAE, and 3MGA were less than
0.7, and those of GCM and ILG were higher than 1.2.
From these results, linearity was observed in Cmax and
AUC0–last for GA. GCM and ILG revealed linearity only in Cmax.
Nonlinearity was observed for ALB, PAE, GCM, and 3MGA,
although these components were detected in the plasma of the
SKT-treated subjects.
DISCUSSION
This is the first study to investigate the pharmacokinetics
of the six types of active components (Paeoniae radix-derived
ALB and PAE and Glycyrrhizae radix-derived GCM, ILG, GA,
and 3MGA) detected in the blood of humans in a randomized
crossover trial. The SKT formulation includes five target com-
ponents. However, the content of GA, a GLmetabolite, was very
low, that is, approximately 1:2000 of GL. It has been demon-
strated that GL is not directly absorbed from the intestinal
tract, that is, GL (glycoside) in theGlycyrrhizae radix is demon-
strated to be metabolized by enteric bacteria and then absorbed
into the blood as either GA (aglycone) or 3MGA.34–38 3MGA is
also the secondary metabolite generated by GA absorbed into
the blood.39 The data of these targeted components were deter-
mined and assured by our validated method, which was estab-
lished for this trial.
Shakuyakukanzoto is reported to rapidly improve symptoms
of suddenly occurringmuscle cramp and abdominal pain. These
pains are triggered by the sudden contraction of skeletal mus-
cles or visceral smooth muscles. SKT has been shown to have
both antimuscle cramps and analgesic effects to these symp-
toms. Muscle contraction is induced by increasing intracellu-
lar Ca2+ concentration via the Ca-induced Ca-release mecha-
nism of the sarcoplasmic reticulum.40,41 The antimuscle cramp
mechanism of SKT works by suppressing the Ca2+ concentra-
tion, and the active component is believed to be Glycyrrhizae
radix-derived ILG, GCM, or GA.8 Further, the analgesic effect
of SKT is believed to suppress the transmission of pain to the
upper central nervous system by suppressing the release of
substance P from the primary afferent fiber via the activation
the descending inhibitory 5-HT and NE neurons in the poste-
rior horn of the spinal cord, and these active components are
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RESEARCH ARTICLE – Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism 3957
T
ab
le
1.
P
h
ar
m
ac
ok
in
et
ic
P
ar
am
et
er
s
of
S
ix
S
h
ak
u
ya
ku
ka
n
zo
to
-D
er
iv
ed
C
om
po
n
en
ts
C
m
ax
(n
g/
m
L
)
A
U
C
0–
la
st
(n
g·h
/m
L
)
t 1
/2
(h
r)
t m
ax
(h
r)
C
om
po
n
en
ts
S
K
T
D
os
e
G
eo
m
et
ri
c
M
ea
n
(9
5%
C
I)
n
G
eo
m
et
ri
c
M
ea
n
(9
5%
C
I)
n
G
eo
m
et
ri
c
M
ea
n
(9
5%
C
I)
n
M
ed
ia
n
(R
an
ge
)
n
A
lb
ifl
or
in
2.
5
g
1.
96
(1
.7
0–
2.
25
)
20
11
.0
(9
.1
5–
13
.2
)
20
1.
81
(1
.5
7–
2.
08
)
19
2.
00
(0
.5
00
–8
.0
0)
20
5.
0
g
2.
14
(1
.7
9–
2.
56
)
20
13
.3
(1
0.
8–
16
.4
)
20
1.
76
(1
.6
3–
1.
90
)
20
2.
00
(0
.5
00
–1
0.
0)
20
P
ae
on
ifl
or
in
2.
5
g
6.
06
(5
.2
3–
7.
01
)
20
34
.7
(2
9.
1–
41
.4
)
20
1.
74
(1
.5
8–
1.
91
)
20
2.
00
(0
.5
00
–8
.0
0)
20
5.
0
g
6.
30
(5
.2
8–
7.
51
)
20
39
.5
(3
1.
9–
48
.8
)
20
1.
73
(1
.6
0–
1.
86
)
20
3.
00
(0
.5
00
–1
0.
0)
20
G
ly
cy
co
u
m
ar
in
2.
5
g
0.
04
49
(0
.0
37
3–
0.
05
41
)
19
0.
03
67
(0
.0
21
9–
0.
06
14
)
19
14
.9
(2
.5
6–
87
.0
)
2
0.
50
0
(0
.2
50
–1
.0
0)
19
5.
0
g
0.
08
85
(0
.0
74
8–
0.
10
5)
20
0.
18
0
(0
.1
21
–0
.2
66
)
20
9.
21
(6
.0
1–
14
.1
)
11
0.
50
0
(0
.2
50
–1
.0
0)
20
Is
ol
iq
u
ir
it
ig
en
in
2.
5
g
0.
15
7
(0
.1
27
–0
.1
93
)
20
0.
09
85
(0
.0
69
8–
0.
13
9)
20
4.
73
(1
.9
0–
11
.8
)
5
0.
25
0
(0
.2
50
–0
.5
00
)
20
5.
0
g
0.
28
8
(0
.2
35
–0
.3
53
)
20
0.
31
0
(0
.2
41
–0
.3
98
)
20
4.
12
(2
.4
2–
7.
02
)
13
0.
25
0
(0
.2
50
–0
.5
00
)
20
G
ly
cy
rr
h
et
ic
ac
id
2.
5
g
11
8
(8
9.
3–
15
6)
20
15
40
(1
23
0–
19
30
)
20
10
.3
(7
.4
9–
14
.3
)
12
10
.0
(8
.0
0–
24
.0
)
20
5.
0
g
21
1
(1
69
–2
63
)
20
28
60
(2
34
0–
34
80
)
20
8.
43
(5
.5
4–
12
.8
)
14
10
.0
(4
.0
0–
24
.0
)
20
G
ly
cy
rr
h
et
ic
ac
id
3-
O
-m
on
og
lu
cu
ro
n
id
e
2.
5
g
1.
14
(0
.9
07
–1
.4
3)
20
11
.4
(8
.6
8–
14
.9
)
20
5.
07
(4
.2
2–
6.
10
)
20
8.
00
(4
.0
0–
8.
00
)
20
5.
0
g
1.
42
(1
.1
7–
1.
73
)
20
15
.3
(1
2.
0–
19
.5
)
20
5.
26
(4
.6
0–
6.
02
)
20
8.
00
(4
.0
0–
8.
00
)
20
S
K
T,
S
h
ak
u
ya
ku
ka
n
zo
to
;C
I,
co
n
fi
de
n
ce
in
te
rv
al
.
believed to be Paeoniae radix-derived ALB and PAE.6 Further,
whereas GA contributes to the efficacy of SKT, GA has also
been thought, along with 3MGA, to be a causal component in
hypokalemia.15–18 For these effects to be manifested, it is nec-
essary at the very least for the active components to transition
into the blood after SKT is orally administered.
In this trial, the six target components were detected in the
blood after the oral administration of SKT. For both the Paeo-
niae radix componentsALBandPAE, an absorption phase of 4 h
and a subsequent elimination phase were recognized (Figs. 3a
and 3b). However, in the linearity analysis, because an increase
in the SKT dose was not accompanied by increased concentra-
tion (Cmax or AUC0–last) in the blood for either ALB or PAE, it
was judged that there was no dose proportionality. Both compo-
nents are absorbed into the intestinal tract as glycosides; how-
ever, because this absorption capacity is low,42 it is conjectured
that the nonlinearitymay have been caused by saturation of the
absorption. Furthermore, portions of both components are me-
tabolized by enteric bacteria and are absorbed into the blood as
aglycone. However, their transition into the blood is considered
to be slow.43 In the absorption phase, both components were
detected in the plasma at the early stage between 5 and 15 min
after the oral administration of SKT. These results suggest that
glycosides are a greater contributing factor than metabolites to
the immediate efficacy of SKT.
The concentration of the Glycyrrhizae radix components
GCM and ILG in the blood demonstrated a bimodal peak after
the oral administration of SKT (Figs. 3c and 3d). The high-
est concentration for both occurred at the first peak: at 15
min for ILG and 30 min for GCM, which reflected extremely
fast absorption. The second low-concentration peaks of these
components were observed 2–3 h after the oral administra-
tion of SKT. Because this bimodality was not observed during
animal tests in the case of intravenous administration,44 the
cause is not considered to be enterohepatic circulation. This
bimodality of ILG is surmised to be because of a difference in
the absorption site of ILG and isoliquiritin metabolite because
ILG is also produced from the glycoside isoliquiritin by enteric
bacteria.10 The t1/2 of both components could be calculated for
only a few subjects because the maximum plasma concentra-
tion (Cmax) of these components was very low (<1 ng/mL) as
compared with that of the Paeoniae radix-derived components
ALB and PAE. An increase in the plasma concentration of ILG
and GCMwas accompanied by an increase in the dosage of SKT
in the case of Cmax; however, this was not observed in the case
of AUC0–last of both components, possibly because the t1/2 value
could not be calculated in a few subjects in the 2.5 and 5.0 g SKT
groups.
On the contrary, intravenous injection of GA has been re-
ported to immediately ameliorate muscle cramps.8 However,
the tmax of GA orally administered as SKT was extremely slow
(10 h) as compared with that of ILG and GCM. GA also slowly
disappeared over the next 8–10 h (t1/2) after reaching tmax. These
results suggest that the Glycyrrhizae radix contains two types
of components. GCM and ILG with rapid tmax are believed to be
responsible for immediate efficacy of SKT together with Paeo-
niae radix-derived components ALB and PAE. GA with slow
tmax and t1/2 is probably thought to be a component that sus-
tains the efficacy of SKT. Thus, the contribution of SKT in pro-
viding analgesic effects and ameliorating muscle cramps may
be attributed to a synergistic effect of various components with
different pharmacokinetic attributes.
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Table 2. Dose Proportionality Analysis
AUC0–last Cmax
Components $ CI Lower CI Upper Intercept $ CI Lower CI Upper Intercept
Albiflorin 0.280 0.0654 0.494 2.14 0.127 −0.128 0.382 0.556
Paeoniflorin 0.187 −0.0378 0.412 3.37 0.0563 −0.205 0.317 1.75
Glycycoumarin 2.27 1.84 2.70 −5.37 0.979 0.777 1.18 −4.00
Isoliquiritigenin 1.65 1.27 2.04 −3.83 0.875 0.681 1.07 −2.65
Glycyrrhetic acid 0.892 0.637 1.15 6.52 0.841 0.593 1.09 4.00
Glycyrrhetic acid 3-O-monoglucuronide 0.433 0.233 0.633 2.03 0.322 0.163 0.481 −0.165
CI, 90% confidence interval.
Another GL metabolite 3MGA, which is also considered to
be a causal component in hypokalemia, showed extremely slow
tmax and t1/2 values, similar to GA. To the best of our knowledge,
this is the first report to show the blood concentration changes
of 3MGA. Our study will provide foundational data to clarify
themechanisms for side effects in the future. Linearity between
the blood pharmacokinetic parameters and the dose of SKTwas
observed in the case of GA; however, no linearity was observed
for 3MGA. In a double-blind study, Kumada et al.45 reported
that the frequency of pseudoaldosteronism or hypokalemia was
extremely low when SKT was administered for 2 weeks. How-
ever, in the monitoring of side effects for other formulation
yokukansan, containing, including Glycyrrhizae radix, devel-
opment of pseudoaldosteronism or hypokalemia has been re-
ported, although at a low frequency.46 Therefore, care must be
taken when using SKT in the clinical settings.
CONCLUSION
In order for SKT to show anticonvulsive, analgesic, andmuscle-
relaxant effects, the active components presumed by the in vivo
and in vitro basic researches must absorb into blood. To our
knowledge, this is the first trial in humans to demonstrate
that these components were absorbed into the blood after the
oral administration of SKT. The results of this pharmacokinetic
trial in humans are important and useful for understanding the
mechanism of action of SKT, verifying the active components
predicted in the basic research, and conducting ADME and
safety studies in the future.
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